Equivalent Systemic Exposure to Fluticasone Propionate/Salmeterol Following Single Inhaled Doses from Advair Diskus and Wixela Inhub: Results of Three Pharmacokinetic Bioequivalence Studies

Scott Haughie, MSc,1 Richard Allan, BSc,1 Nolan Wood, PhD,2 and Jon Ward, PhD1

Abstract

Background: Wixela® Inhub® was developed to deliver inhaled fluticasone propionate/salmeterol (FP/S) combination as a substitutable generic equivalent to Advair® Diskus®. These studies aimed to confirm the pharmacokinetic bioequivalence (BE) of FP/S after single doses of Wixela Inhub (test [T]) and Advair Diskus (reference [R]).

Methods: Three open-label, randomized, two-way crossover, single-dose studies in healthy subjects (N = 66 each) compared the systemic exposure of FP and salmeterol after inhalation from three dose strengths of FP/S (100/50, 250/50, or 500/50 µg) delivered from T and R. Primary BE endpoints were the area under the plasma concentration-time curve from time = 0 to the last measurable concentration (AUC(0-t)) and the maximum observed plasma concentration (Cmax) for both FP and S. The BE acceptance criteria specified that the 90% confidence intervals (CIs) of the geometric mean T/R ratios for AUC(0-t) and Cmax can be contained within 0.80–1.25 for both FP and salmeterol.

Results: Wixela Inhub met the acceptance criteria for BE for FP and salmeterol at each dose strength. Estimated AUC(0-t) and Cmax geometric mean ratios (T/R [90% CI]) for FP were, respectively, 1.04 (1.00–1.08) and 0.92 (0.87–0.96) for 100/50 µg FP/S, 1.07 (1.02–1.13) and 1.01 (0.95–1.07) for 250/50 µg, and 0.97 (0.92, 1.00) and 0.90 (0.86–0.93) for 500/50 µg. Estimated AUC(0-t) and Cmax ratios for salmeterol were, respectively, 1.08 (1.04–1.11) and 1.00 (0.94–1.04) for 100/50 µg FP/S, 1.03 (0.99–1.07) and 0.93 (0.87–1.00) for 250/50 µg, and 1.00 (0.96–1.04) and 0.86 (0.81–0.91) for 500/50 µg. FP/S at all doses via both T and R was comparably well tolerated.

Conclusions: Wixela Inhub was bioequivalent to Advair Diskus at all three dose strengths for both FP and S, providing direct evidence of equivalent systemic safety and indirect evidence for equivalent pulmonary deposition.

Keywords: Advair Diskus, asthma, COPD, fluticasone propionate, pharmacokinetic bioequivalence, salmeterol, Wixela Inhub

Introduction

A combination of oral inhaled corticosteroids (ICS) and long-acting β2-adrenergic agonists (LABAs) is recommended for patients with asthma not controlled with ICS alone and for patients with chronic obstructive pulmonary disease (COPD) at high risk of exacerbations.1–4 Fluticasone propionate/salmeterol (FP/S) dry powder inhaler is a widely prescribed ICS/LABA fixed-dose combination drug, marketed in the United States as Advair® Diskus® (GlaxoSmithKline, Research Triangle Park, NC). Advair Diskus is available in three strengths, described according to the variable nominal FP dose and acknowledging the fixed 50 µg nominal dose of salmeterol base in each strength in µg:
100/50, 250/50, and 500/50. All three strengths are licensed for the twice-daily treatment of adult and adolescent asthma, the 100/50 µg strength for the management of pediatric asthma (≥24 years), and the 250/50 µg strength for the treatment of COPD.

With the expiration of U.S. patent protection for Advair Diskus in 2016, generic versions of the drug are progressing toward approval of an abbreviated new drug application (ANDA) by the U.S. Food and Drug Administration (FDA).<ref><sup>(6,7)</sup></ref> The most advanced generic is Wixela® Inhub® (previously known as MGR001; Mylan, Inc., Canonsburg, PA), which delivers FP/S from a novel multidose dry powder inhaler (Inhub® device, previously known as CRC749).<ref><sup>(8,9)</sup></ref> A clinical development program for Wixela Inhub has been completed, and an ANDA has recently been approved.<ref><sup>(10)</sup></ref> As part of the clinical development plan for a substitutable generic equivalent of FP/S, the FDA requires the conduct of a pharmacokinetic (PK) bioequivalence (BE) study for each of the dose strengths approved for Advair Diskus.<ref><sup>(11)</sup></ref> Here, we report the results of three PK BE studies conducted in support of the development of Wixela Inhub.

The studies were all conducted in healthy male and female volunteers, with one study for each at the 100/50, 250/50, and 500/50 µg FP/S dose strengths. The objective of each study was to confirm the systemic PK BE of FP and salmeterol after oral inhalation of single doses of Wixela Inhub and Advair Diskus.

Materials and Methods

In this article, “test product” (T) and “reference product” (R)<sup>(11)</sup> are defined as follows: T is Wixela Inhub (FP/S administered via the Inhub device), R is Advair Diskus. Both products contained 60 metered individual doses. Each dose of Advair Diskus comprised a white powder mix of micronized FP (100, 250, or 500 µg) and micronized salmeterol xinafoate salt (72.5 µg, equivalent to 50 µg of salmeterol base) in a 12.5 µg of formulation containing lactose monohydrate (as an excipient). The formulation contained within Wixela Inhub is qualitatively and quantitatively equivalent to that contained within Advair Diskus in terms of both active (FP and salmeterol [as xinafoate]) and inactive (lactose monohydrate) ingredients.

Study design and conduct

Three open-label, randomized, two-way crossover studies were conducted at a single clinical center in the United States between April 2015 and July 2017, each under a separate protocol. Each study compared the systemic exposure of FP and salmeterol after FP/S administration of T and R at one of the three Advair Diskus dose strengths (FP/S 100/50, 250/50, or 500/50 µg) authorized in the United States. Study 1 evaluated FP/S 100/50 µg, study 2 evaluated FP/S 250/50 µg, and study 3 evaluated FP/S 500/50 µg. The objective of each study was to confirm the PK BE of both FP and salmeterol after oral inhalation of single doses of T and R.

The studies conformed to appropriate ethical guidelines and were conducted in accordance with the principles of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use guideline for good clinical practice<sup>(12)</sup> and the code of ethics of the World Medical Association’s Declaration of Helsinki.<ref><sup>(13)</sup></ref> Each study protocol was approved by an appropriate institutional review board, and all patients provided written informed consent.

Study subjects and treatments

Each study was conducted in 66 healthy male and female subjects who received single orally inhaled doses of both T and R, one per study period, with a minimum 7-day washout in between. Subjects were excluded if they had used any prescription or nonprescription drugs within 7 days of the start of the study, had abnormal lung function (forced expiratory volume in 1 second <80% of predicted), or were current smokers, ex-smokers who had given up smoking for <6 months, and/or had a smoking history of ≥10 pack-years.

Each study had an identical two-treatment, two-period crossover design (2×2), with subjects randomized equally to each treatment sequence. To obtain adequate plasma FP and salmeterol levels, each FP/S dose strength was administered as three inhalations, resulting in total FP/S doses of 300/150 µg (study 1), 750/150 µg (study 2), and 1500/150 µg (study 3). This was implemented to ensure that both FP and salmeterol were detectable for at least three half-lives for each analyte after dosing, thus allowing an appropriate estimation of the PK parameters. In addition, the use of three inhalations was expected to reduce variability and ensure a variation coefficient (CV) of <30% for all of the BE endpoints. Based on the performance of the reference product determined in an exploratory PK study, a prospective agreement was obtained from the US FDA that the use of three inhalations was appropriate based on their stated requirement that the dose chosen should comprise the “Minimum number of inhalations that is sufficient to characterize a PK profile by using a sensitive analytical method.”<ref><sup>(11)</sup></ref> To ensure consistent dosing, subjects received inhalation training on day –1 and day 1 (before treatment). Treatments were administered after an 8-hour fast, and standard meals were provided at ~4 and 9–10 hours postdose and appropriate times thereafter. Water was allowed ad libitum throughout the study except during the period from 1 hour before dose through to 1 hour postdose.

PK assessments and endpoints

For each study, plasma samples were obtained for each treatment period before dosing and at 2, 5, 10, 15, 20, 30, and 45 minutes and 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, and 48 hours postdose. Sampling started at 2 minutes postdose to ensure that peak plasma concentrations of salmeterol were adequately captured, and continued up to 48 hours postdose to ensure coverage of at least three times the terminal elimination half-life (T<sub>1/2</sub>) estimates of the FP and salmeterol components. Drug concentrations were analyzed using validated high-performance liquid chromatography tandem mass spectrometry with a lower limit of quantification of 1 pg/mL.

Primary PK endpoints were area under the plasma concentration-time curve from time = 0 to the last measurable plasma drug concentration (AUC<sub>(0-∞)</sub>) and maximum observed plasma drug concentration (C<sub>max</sub>) for both FP and salmeterol. PK parameters were derived by using
noncompartmental methods using Phoenix® WinNonlin® (version 6.3; Certara L.P. [Pharsight], St. Louis, MO). Safety assessments included adverse events (AEs), electrocardiograms, vital signs (blood pressure and pulse rate), cardiac telemetry, and laboratory safety tests.

**Statistical methods**

The safety population comprised all randomized subjects who received at least one treatment. PK parameters were calculated for all subjects who completed at least one treatment period, and those subjects who had calculable values for at least one of the primary PK parameters in at least one period were included in the PK parameter set. The statistical analysis of BE was conducted using a predefined PK analysis set (subjects who completed both treatment periods, had calculable values for at least one of the primary endpoints in both periods, and did not experience any protocol deviations or AEs that would affect PK).

Sample size calculations were based on salmeterol C\text{max}, since from previous Mylan studies (data on file), this PK parameter exhibits a greater within-subject standard deviation (WSD) than salmeterol AUC\text{0-\text{t}}, FP C\text{max}, or FP AUC\text{0-\text{t}} (values for salmeterol C\text{max} WSD in the range 0.22–0.28 on the natural log scale). Using a WSD of 0.22 and a one-sided significance level \(\alpha=0.05\), sample size calculations indicated that 62 subjects in the PK analysis set gave 90% power (true difference in means of log\[0.9\]), and a WSD of 0.28 gave 80% power (true difference in means of log\[1.1\]) to demonstrate BE. Thus, a total of 66 subjects were randomized in each study to give at least 62 in the PK analysis set.

Primary endpoints (AUC\text{0-\text{t}} and C\text{max}) were analyzed by using analysis of variance (ANOVA), allowing for variation due to sequence, subject within sequence, period, and treatment. The analysis was performed on the natural log scale. Least-squares mean differences (plus standard errors and 90% confidence intervals [CIs]) were produced on the log scale and exponentiated to give ratios of geometric means and associated 90% CIs on the original scale. To demonstrate BE at each dose strength\(^{(11)}\) the 90% CIs of the T to R geometric mean ratios for AUC\text{0-\text{t}} and C\text{max} were each required to be wholly contained within the interval 0.80–1.25 (i.e., 80%–125%) for both the FP and salmeterol components. PK parameters and AEs were summarized by using descriptive statistics. All statistical analyses were conducted by using SAS® version 9.3 (Cary, NC).

**Results**

**Subjects**

For each of the three studies (\(N=66\) for each study), all subjects completed treatment period 1 and were analyzed for safety and PK parameters; of the 198 randomized subjects across the three studies, 192 subjects also completed treatment period 2 and 190 were included in the PK analysis set (Fig. 1). Of the six subjects who did not complete treatment period 2, three subjects discontinued due to an AE and three subjects discontinued due to protocol deviations. Key baseline characteristics (age, body mass index, and tobacco history) were comparable across the three studies (Table 1).

**FIG. 1.** Subject disposition.
BMI, mean
Race, n
Age, mean (range), years 33.8 (19–53) 37.7 (18–55) 35.7 (19–53)

PK BE assessments

Fluticasone propionate. In each study, the plasma FP concentration versus time data for T and R were comparable (Fig. 2, left panels); thus, the FP PK parameters for T and R were also comparable (Table 2). FP was rapidly absorbed, with Tmax values ranging from 0.75 hours (study 1) to 1.5 hours (study 3). Mean Cmax values were dose–dependent, increasing from 109 pg/mL (study 1) to 290 pg/mL (study 3). Mean total systemic FP exposure (AUC(0-t)) was similarly dose dependent, increasing from 609 pg*h/mL (study 1) to 2919 pg*h/mL (study 3). Mean T1/2 values were similar across each dose strength, ranging from 9.95 hours (study 1) to 12.23 hours (study 3).

For each of the FP/S dose strengths, the geometric mean T/R ratios and 90% CIs were between 0.80 and 1.25 for FP AUC(0,t) and FP Cmax (Table 3), indicating that T and R were bioequivalent for the FP component.

Salmeterol. In each study, the plasma salmeterol concentration versus time data for T and R were comparable (Fig. 2, right panels); thus, the salmeterol PK parameters for T and R were also comparable (Table 2). Salmeterol was very rapidly absorbed, with a Tmax value of 5 minutes across the three studies. Mean Cmax values were consistent across studies, ranging from 319 pg/mL (study 2) to 418 pg/mL (study 3). Mean AUC(0,τ) was similarly consistent, ranging from 677 pg*h/mL (study 1) to 724 pg*h/mL (study 3). Mean T1/2 values were also consistent, ranging from 11.21 hours (study 2) to 12.21 hours (study 1).

For each of the FP/S dose strengths, the 90% CI of the geometric mean T/R ratios for salmeterol AUC(0,τ) and salmeterol Cmax were between 0.80 and 1.25 (Table 3), indicating that T and R were bioequivalent for the salmeterol component.

Safety results

FP/S was well tolerated for both T and R in all studies with no clinically significant changes in electrocardiograms, vital signs (blood pressure and pulse rate), cardiac telemetry, or laboratory safety tests. AEs were generally mild and occurred with similar frequencies in T- and R-treated subjects in all studies (Table 4). The most commonly reported AE was headache. One subject experienced a serious AE, classified as dyspnea of moderate severity, that occurred after completion of treatment with R in study 1 (100/50 μg dose strength) and was considered by the investigator not to be treatment related. One subject treated with T in study 1 experienced an upper respiratory tract infection of mild severity (considered by the investigator to be unrelated to treatment) that led to discontinuation.

Discussion

Wixela Inhub is being developed as a generic equivalent to Advair Diskus. These studies, one for each of the three authorized Advair Diskus dose strengths, confirmed the PK BE of both FP and salmeterol components after oral inhalation of single doses of Wixela Inhub and Advair Diskus. For the FP/S 100/50 μg, 250/50 μg, and 500/50 μg dose strengths, BE criteria were fully met for both FP and salmeterol for each primary endpoint (AUC(0,τ) and Cmax), in accordance with regulatory guidance (11). PK parameters for FP and salmeterol after treatment with FP/S were consistent with published data on Advair Diskus (14–18); however, the higher total FP/S doses of the current studies (300/150, 750/150, and 1500/150 μg) complicate a direct comparison of PK parameters with those from previous studies, which used lower total doses (100/50 and 250/50 μg). The use of higher total FP/S doses (three inhalations) in the current studies allowed for a thorough understanding of the PK profile of both FP and salmeterol from both Wixela Inhub and Advair Diskus, including an assurance that the plasma concentrations of each analyte were readily detectable to at least 12 hours postdose, and thus enabled a complete comparison of both T and R. In addition, the use of three inhalations of FP/S is associated with less variability of exposure, particularly for the 100/50 μg strength (within subject CV <30%), compared with the same dose administered with one inhalation (within subject CV >30% [Mylan data on file]).

Within each dose strength, FP and salmeterol PK parameters for T and R were similar. Peak plasma concentrations of FP and salmeterol occurred at 1–2 hours and 5 minutes, respectively, as previously reported (18,19). The mean T1/2 estimated for FP in these studies (11.01 hours)
was longer than some previous reports (4.7 hours\textsuperscript{(17)} and 7.8 hours\textsuperscript{(18)}) and similar to other estimates (11.4 hours\textsuperscript{(20)} and 12.5 hours\textsuperscript{(21)}). This increased T\textsubscript{1/2} could be a reflection of the fact that in this study three inhalations of FP/S were given, which meant that concentrations were sufficient to allow thorough characterization of the terminal phase. Therefore, the reported half-lives in this study are considered accurate.

Burmeister-Getz et al.\textsuperscript{(21)} have reported that for Advair Diskus 100/50 \(\mu\)g, the inherent variability of R means it is not likely that a 2\(\times\)2 comparison of a generic FP/S with Advair Diskus would achieve BE according to current FDA standards; our studies are counter to this position. It is recognized that variability exists in the PK response to Advair Diskus; however, if appropriate \emph{in vitro} assessments such as fine particle mass (FPM) are performed across a large range of batches of Advair Diskus, it is possible to characterize the population of Advair Diskus batches. While remaining within the pharmaceutical specification for Advair Diskus, batches of R that are near the extremes of the distribution exist (e.g., a batch that has high FPM and another batch that has low FPM), and if such batches are compared, they can be shown not to be bioequivalent in a standard human PK study (Mylan data on file). However, if the comparison between the same two batches is corrected for the FPM content, they can be shown to be bioequivalent by using the same study data. The Burmeister-Getz et al.\textsuperscript{(21)} study did not report the key \emph{in vitro} characteristics of the batches of Advair Diskus used, reporting only the age of the batches, which is not an

**FIG. 2.** Plasma FP (left panels) and plasma salmeterol (right panels) versus time data after administration of FP/S to healthy subjects (T [closed circles] or R [open circles]) in studies 1, 2, and 3. Data presented are arithmetic mean plasma concentration (semilog scale) \((n = 62-66)\). FP/S, fluticasone propionate/salmeterol.
| Treatment | Study 1 | Study 2 | Study 3 |
|-----------|---------|---------|---------|
|           | FP/S 100/50 µg | FP/S 250/50 µg | FP/S 500/50 µg |
| Device    | T (n=65) | R (n=65) | T (n=65) | R (n=64) | T (n=65) | R (n=66) |
|           |          |         |          |         |          |         |
| **FP PK parameters** |          |         |          |         |          |         |
| T<sub>max</sub>, h | 0.75 (0.08–1.50) | 0.75 (0.08–1.50) | 1.00 (0.08–3.00) | 1.00 (0.33–3.01) | 1.50 (0.33–4.00) | 1.50 (0.33–4.00) |
| C<sub>max</sub>, pg/mL | 109.7±36.2 | 118.6±35.5 | 170.0±53.7 | 173.6±56.4 | 261.6±69.1 | 290.9±74.0 |
| AUC<sub>(0–t)</sub>, pg·h/mL | 638±201 | 609±179 | 1298±418 | 1237±379 | 2851±970 | 2919±831 |
| T<sub>1/2</sub>, h | 10.18±2.46<sup>b</sup> | 9.95±2.77<sup>d</sup> | 11.24±1.80<sup>e</sup> | 10.38±1.71<sup>f</sup> | 12.23±2.68<sup>c</sup> | 10.57±1.90 |
| **Salmeterol PK parameters** |          |         |          |         |          |         |
| T<sub>max</sub>, h | 0.08 (0.03–1.50) | 0.08 (0.03–2.00) | 0.08 (0.04–1.01) | 0.08 (0.05–2.01) | 0.08 (0.03–1.00) | 0.08 (0.03–1.50) |
| C<sub>max</sub>, pg/mL | 385.4±162.8 | 379.3±143.9 | 319.5±137.8 | 352.8±158.1 | 376.6±181.3 | 418.0±145.8 |
| AUC<sub>(0–t)</sub>, pg·h/mL | 727±223 | 677±245 | 700±340 | 686±324 | 724±297 | 708±236 |
| T<sub>1/2</sub>, h | 11.87±1.54<sup>c</sup> | 12.21±1.93 | 11.55±1.71 | 11.66±1.86<sup>e</sup> | 11.21±2.01 | 11.56±1.86<sup>d</sup> |

Data are shown as arithmetic mean±standard deviation for all parameters except T<sub>max</sub>, which is shown as median (range).

<sup>a</sup>Three inhalations in each study, resulting in total FP/S doses of 300/150 µg (study 1), 750/150 µg (study 2), and 1500/150 µg (study 3).

<sup>b</sup>n=62.
<sup>c</sup>n=64.
<sup>d</sup>n=60.
<sup>e</sup>n=63.
<sup>f</sup>n=59.
<sup>g</sup>n=65.

AUC<sub>(0–t)</sub>, area under the concentration-time curve from time = 0 to the last measurable concentration; C<sub>max</sub>, maximum plasma concentration; FP, fluticasone propionate; FP/S, fluticasone propionate/salmeterol; h, hours; PK, pharmacokinetic; R, reference product (Advair<sup>®</sup> Diskus<sup>®</sup>); T, test product (Wixela<sup>®</sup> Inhub<sup>®</sup>); T<sub>1/2</sub>, terminal elimination half-life; T<sub>max</sub>, time to maximum plasma concentration.
adequate indicator of pharmaceutical performance of the product. However, if batches of both T and R are well matched for in vitro parameters, and the R batch is representative of the Advair Diskus population, then PK BE can be achieved as demonstrated in these studies for all dose strengths of FP/S.

In addition, Burmeister-Getz et al. (19) have reported that variability of product batches may lead to an increase in type 1 error rate beyond the accepted 5% level by using the standard 2×2 crossover design. The assumption underlying this finding is that batches of T and R included in a PK study are chosen entirely at random (i.e., selected from any point

| Study 1: FP/S 100/50 μg (n = 64) | AUC_{(0-t)} (pg·h/mL) | AUC_{(0-t)} T/R ratio (90% CI) | C_{max} (pg/mL) | C_{max} T/R ratio (90% CI) |
| Fluticasone propionate | T 600.3 | 1.04 (1.00–1.08) | 103.7 | 0.92 (0.87–0.96) |
| | R 576.4 | | 112.9 | |
| Salmeterol | T 696.4 | 1.08 (1.04–1.11) | 347.7 | 1.00 (0.94–1.04) |
| | R 644.9 | | 348.3 | |

| Study 2: FP/S 250/50 μg (n = 61) | Fluticasone propionate | T 1251 | 1.07 (1.02–1.13) | 164.2 | 1.01 (0.95–1.07) |
| | R 1164 | | 162.7 | |
| Salmeterol | T 641.2 | 1.03 (0.99–1.07) | 296.2 | 0.93 (0.87–1.00) |
| | R 623.3 | | 317.4 | |

| Study 3: FP/S 500/50 μg (n = 65) | Fluticasone propionate | T 2689 | 0.97 (0.92–1.00) | 252.8 | 0.90 (0.86–0.93) |
| | R 2783 | | 281.8 | |
| Salmeterol | T 672.3 | 1.00 (0.96–1.04) | 334.9 | 0.86 (0.81–0.91) |
| | R 670.8 | | 388.6 | |

Data presented as natural-log transformed geometric mean (based on least squares mean).

Three inhalations were administered in each study, resulting in total FP/S doses of 300/150 μg (study 1), 750/150 μg (study 2), and 1500/150 μg (study 3).

In addition, Burmeister-Getz et al. (19) have reported that variability of product batches may lead to an increase in type 1 error rate beyond the accepted 5% level by using the standard 2×2 crossover design. The assumption underlying this finding is that batches of T and R included in a PK study are chosen entirely at random (i.e., selected from any point

Table 4. Safety Overview (Safety Population)

| Treatmenta | Study 1 | Study 2 | Study 3 |
| --- | --- | --- | --- |
| | 100/50 μg | 250/50 μg | 500/50 μg |
| Device | T (n=65) | R (n=65) | T (n=64) | R (n=64) | T (n=65) | R (n=66) |
| Subjects reporting ≥1 treatment-emergent AE, n (%) | 4 (6.2) | 9 (13.8) | 11 (16.9) | 5 (7.8) | 4 (6.2) | 0 |
| Subjects reporting ≥1 serious AE, n (%) | 0 | 1 (1.5)b | 0 | 0 | 0 | 0 |
| Subjects reporting ≥1 AE leading to study discontinuation, n (%) | 1 (1.5)c | 0 | 1 (1.5) | 1 (1.6) | 0 | 0 |
| Most commonly reported AEs^d, n (%) | | | | | | |
| Headache | 1 (1.5) | 2 (3.1) | 0 | 2 (3.1) | 0 | 0 |
| Dizziness | 0 | 1 (1.5) | 1 (1.5) | 0 (0.0) | 0 | 0 |
| Vessel puncture site pain | 0 | 0 | 3 (4.6) | 2 (3.1) | 0 | 0 |
| Presyncope | 1 (1.5) | 1 (1.5) | 2 (3.1) | 0 (0.0) | 0 | 0 |

a Three inhalations were administered in each study, resulting in total FP/S doses of 300/150 μg (study 1), 750/150 μg (study 2), and 1500/150 μg (study 3).

b One case of moderate dyspnea was reported 2 days 7 hours after FP/S administration and after completion of all study procedures; this AE was considered by the investigator as not related to study treatment.

c One nonserious case of mild upper respiratory tract infection led to discontinuation of this subject before period 2; this AE was considered by the investigator as not related to study treatment.

^d AEs (preferred terms) reported by two or more subjects with any treatment.

AE, adverse event; FP/S, fluticasone propionate/salmeterol; R, reference product (Advair® Diskus®); T, test product (Wixela® Inhub®).
of the distribution for each product). The source of the inflated type I error is the overlap of the distribution of the individual T and R batches around the respective T and R averages. In general, the greater the interbatch variability, the wider this overlap, and the greater the chance of the erroneous finding that batches are bioequivalent, even if the product averages are not bioequivalent.

Recently, the same authors(22) presented the results of a PK study utilizing a multibatch design, which demonstrated BE for OT329 Solis 100/50 μg versus Advair Disks 100/50 μg. This study design was not consistent with FDA guidance(11) but represented a novel, unprecedented approach to demonstrating PK BE, which was presumably developed to resolve the authors’ concerns about the properties of standard PK BE designs raised in earlier publications. Although this and other multibatch approaches are still very much in their infancy,(21) we believe that the standard PK BE designs we have utilized, in combination with a thorough understanding of the in vitro characteristics that drive interbatch variability of both T and R, and well-established statistical analysis methods, still represent a robust and reliable assessment of the PK BE of FP/S combination products, in line with FDA guidance.

The recruitment of healthy subjects instead of subjects with asthma or COPD enabled a comprehensive assessment of systemic exposure of FP and salmeterol without the potential confounding factors such as variable and compromised pulmonary function or the use of concomitant medications, all of which could have a direct influence on the absorption, distribution, metabolism, and excretion of the study drugs. As the use of healthy subjects allows for consistent disease status and no requirement to modulate a study is reduced substantially. Likely for these reasons, the use of healthy volunteers is reflected in regulatory guidance.(11) and healing subjects(14,23) In addition, a meta-analysis(24) demonstrated that drive interbatch variability of both T and R, and well-studied statistical analysis methods, still represent a robust and reliable assessment of the PK BE of FP/S combination products, in line with FDA guidance.

The authors acknowledge Cynthia A. Zamora, MD, who was the clinical site principal investigator for these studies.

In conclusion, our investigation confirmed that Wixela Inhub demonstrated systemic PK BE to Advair Diskus at all FP/S dose strengths using a consistent approach, with standard study designs for all FP/S dose strengths. Moreover, a study using clinical efficacy endpoints recommended by the FDA(11) has recently been completed as part of the Wixela Inhub clinical development plan (NCT02245672). That study demonstrated local (lung) BE of Wixela Inhub and Advair Diskus in patients with asthma based on the effects of both active treatments on lung function endpoints (forced expiratory volume in 1 second) measured after the first dose and 4 weeks of dosing that were both superior to placebo and statistically equivalent to each other.(23) Wixela Inhub, therefore, represents a substitutable generic equivalent FP/S treatment option for subjects with asthma whose symptoms are uncontrolled with ICS alone and for subjects with COPD at high risk of exacerbations.

**Acknowledgments**

Mylan, Inc., (Canonsburg, Pennsylvania, USA) provided funding for medical writing and editorial support. The authors wish to acknowledge Roger Hill, PhD, for medical writing and Paula Stockart for editorial assistance in the preparation of this article (Ashfield Healthcare Communications, Middletown, CT).

The authors acknowledge Helen Bridger and Bruce Williams (Mylan) for clinical operations related to the studies.

The authors acknowledge Cynthia A. Zamora, MD, Worldwide Clinical Trials Early Phase Services, LLC, 2455 NE Loop 410, Suite 150, San Antonio, Texas, USA, 78217, who was the clinical site principal investigator for these studies.

**Author Disclosure Statement**

Authors S.H., R.A., and J.W. are employees of Mylan and have stock ownership in Mylan. Author N.W. is a former employee of Mylan.

**References**

1. GOLD: Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2017. http://bit.ly/2hNAJ9K. Accessed June 1, 2018.
2. McKeage K, and Keam SJ: Salmeterol/fluticasone propionate: A review of its use in asthma. Drugs. 2009;69:1799–1828.
3. NAEPP: Expert Panel Report 3: Guidelines for the diagnosis and management of asthma. 2007. http://bit.ly/e2GMTzJ. Accessed June 1, 2018.
4. Yawn BP, Raphiou I, Hurley JS, and Dalal AA: The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD. Int J Chron Obstruct Pulmon Dis. 2010;5:165–178.
5. Business Insider: The 10 best selling prescription drugs in the united states. 2012. https://goo.gl/eFAp9i. Accessed June 1, 2018.
6. Steinfeld J, Yiu G, and Miller SD: Dose-ranging study to evaluate the efficacy and safety of four doses of fluticasone propionate/salmeterol multidose dry powder inhaler
(fs mdpi) compared with fluticasone propionate (FP) MDPI and FS DPI in subjects with persistent asthma. J Allergy Clin Immunol. 2015;135:AB6 [Abstract].
7. Maneechotsuwan KP, Assawabhumi X, Rattanasangloet K, Suthamsmai T, Pipopsuthipaiboon S, and Udompunturak S: Comparison between the effects of generic and original salmeterol/fluticasone combination (SFC) treatment on airway inflammation in stable asthmatic patients. J Med Assoc Thai. 2014;97:S91–S100.
8. Clinicaltrials.gov: An open study to assess the robustness of the CRC749 inhaler. 2015. https://goo.gl/MHLv4M. Accessed June 1, 2018.
9. Clinicaltrials.gov: MGR001/Advair Diskus local equivalence study in asthma. 2015. https://goo.gl/q6Is7x. Accessed June 1, 2018.
10. Mylan, Inc. Mylan’s ANDA for generic Advair Diskus® accepted for filing by FDA. 2016. http://goo.gl/OyyvDE. Accessed June 1, 2018.
11. FDA: Draft guidance on fluticasone propionate; salmeterol xinafoate. 2013. http://bit.ly/2eZWWEv. Accessed June 1, 2018.
12. ICH: Integrated addendum to ICH harmonised guideline: Guideline for good clinical practice E6 (R2). 2015. https://goo.gl/CFOmR3. Accessed June 1, 2018.
13. Helsinki: World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA. 2013;310:2191–2194.
14. Mehta R, Daley-Yates PT, Jenkins K, Bianco J, Stylianou A, Louey MD, and Chan RH: Pharmacokinetics of fluticasone propionate and salmeterol delivered as a combination dry powder via a capsule-based inhaler and a multidose inhaler. Pulm Pharmacol Ther. 2014;29:66–73.
15. Mehta R, Riddell K, Gupta A, Louey MD, and Chan RH: Comparison of the pharmacokinetics of salmeterol and fluticasone propionate 50/100 microg delivered in combination as a dry powder via a capsule-based inhaler and a multi-dose inhaler. Clin Drug Invest. 2015;35:319–326.
16. Daley-Yates PT, Mehta R, Chan RH, Despa SX, and Louey MD: Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthmatic and COPD patients. J Aerosol Med Pulm Drug Deliv. 2014;27:279–289.
17. Daley-Yates PT, Parkins DA, Thomas MJ, Gillett B, House KW, and Ortega HG: Pharmacokinetic, pharmacodynamic, efficacy, and safety data from two randomized, double-blind studies in patients with asthma and an in vitro study comparing two dry-powder inhalers delivering a combination of salmeterol 50 microg and fluticasone propionate 250 microg: Implications for establishing bioequivalence of inhaled products. Clin Ther. 2009;31:370–385.
18. GlaxoSmithKline: ADVAIR DISKUS prescribing information. 2016. http://bit.ly/2gah56P. Accessed June 1, 2018.
19. Burmeister-Getz E, Carroll KJ, Mielke J, Benet LZ, and Jones B: Between-batch pharmacokinetic variability inflates type i error rate in conventional bioequivalence trials: A randomized Advair Diskus clinical trial. Clin Pharmacol Ther. 2016;101:331–340.
20. Thorsson L, Edshücker S, Källén A, and Löfdahl CG: Pharmacokinetics and systemic activity of fluticasone via Diskus and pMDI, and of budesonide via Turbuhaler. Br J Clin Pharmacol. 2001;52:529–538.
21. Burmeister-Getz E, Carroll KJ, Jones B, and Benet LZ: Batch-to-batch pharmacokinetic variability confounds current bioequivalence regulations: A dry powder inhaler randomized clinical trial. Clin Pharmacol Ther. 2016;100:223–231.
22. Burmeister-Getz E, and Carroll KJ: Pharmacokinetic bioequivalence of two fluticasone propionate/salmeterol dry powder inhalers, OT329 Solis, and Advair Diskus. CHEST. 2017;152:A768 [Abstract].
23. Mehta N, Aggarwal B, Gogtay J, and Abdool-Gaffar S: Comparing the efficacy and safety of salmeterol/fluticasone pMDI versus its mono-components, other LABA/ICS pMDIs and salmeterol/fluticasone Diskus in patients with asthma. Expert Opin Drug Deliv. 2015;12:963–975.
24. Daley-Yates PT, Tournant J, and Kunka RL: Comparison of the systemic availability of fluticasone propionate in healthy volunteers and patients with asthma. Clin Pharmacokinet. 2000;39 Suppl 1:39–45.
25. Allan R, Kerwin E, White M, Miller D, Haughie S, Ward J, and Ng D: Pulmonary Therapeutic Bioequivalence of WixelaTM InhubTM and Advair Diskus® in Adults with Asthma. American Thoracic Society International Conference, 2019 (in press).

Received on March 27, 2019
in final form, June 17, 2019

Reviewed by:
Ronald Wolff

Address correspondence to:
Scott Haughie, MSc
Mylan Pharma UK Ltd.
The Gateway
Discovery Park
Sandwich CT13 9FF
United Kingdom

E-mail: scott.haughie@mylan.co.uk